Aaron Gerds is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 726 publications with 7,044 citations (h-index 42); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9500 Euclid Ave R35
Cleveland, OH 44195
Telephone
216-445-9840Registry record last updated 22 Dec 2014.
Clinical trials
- Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Sponsor: Icahn School of Medicine at Mount Sinai
- Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms
Sponsor: Case Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20254 payments
- Geron CorporationProgram year20252 payments
- Karyopharm Therapeutics Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
94%Kinase inhibitor47.5%Jakafi88%Ayvakit8%Vonjo4%Part D<11 patientsJanus-associated kinase (JAK) inhibitors23.8%Ojjaara100%Part D≥23 patients+ 3 more classes in this area
Dermatology
4.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.2%Acyclovir100%Part D<11 patientsGenitourinary & hormones
1.9%Androgen1.9%Danazol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
Case Western Reserve University
FY2026$1,218,418UG1CA233234 - Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
Case Western Reserve University
FY2025$1,412,352UG1CA233234 - Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
Case Western Reserve University
FY2024$1,279,477UG1CA233234
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Lars Svensson, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Gene Barnett, MD
Cleveland Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”